Circulating cell-free DNA (cfDNA) has been suggested as a cancer biomarker. Several
studies assessed the usefulness of quantitative and qualitative tumor-specific alterations of …

The aim of the present study was to perform a systematic review of published studies to
provide a robust estimation of the use of procalcitonin (ProCT) as a diagnostic marker of …

Circulating tumor DNA (ctDNA) is now being extensively studied as it is a noninvasive “real-
time” biomarker that can provide diagnostic and prognostic information before, during …

Qualitative and quantitative analysis of circulating cell-free DNA (cfDNA) is an emerging non-
invasive blood biomarker utilized to assess tumor progression and to evaluate prognosis …

Despite all the advances in diagnosis and treatment of breast cancer, a large number of
patients suffer from late diagnosis or recurrence of their disease. Current available imaging …

Background: Liquid biopsies using circulating tumor DNA (ctDNA) and cell-free DNA
(cfDNA) have been developed for early cancer detection and patient monitoring. To …

Alterations of genetic and epigenetic features can provide important insights into the natural
history of breast cancer. Although DNA methylation analysis is a rapidly developing field, a …

Epigenetic biomarkers, such as DNA methylation, can increase cancer risk through altering
gene expression. The Cancer Genome Atlas (TCGA) Network has demonstrated breast …

Background In patients with hormone receptor-positive breast cancer, differentiating
between patients with a low and a high risk of recurrence is an ongoing challenge. In current …

The need for additional breast cancer screening tools is indisputably high, as one may
conclude from the high rate of interval malignancies in women undergoing regular …